SLAMF7激活可恢复系统性红斑狼疮中缺陷的效应CD8+ T细胞功能
本研究通过流式细胞术分析SLE患者与健康对照外周血CD8+ T细胞亚群分布、SLAMF7表达及胞溶酶表达,并评估抗SLAMF7抗体对病毒抗原刺激下CD107a表达、IFNγ产生及细胞毒活性的影响。结果显示SLE患者效应CD8+ T细胞亚群减少、记忆CD8+ T细胞SLAMF7表达降低,SLAMF7交联可增强脱颗粒能力、IFNγ阳性细胞比例及靶细胞裂解,提示SLAMF7单抗可能恢复SLE患者抗病毒效应功能。
要点
- SLE患者外周血CD8+ T细胞亚群分布改变,效应细胞亚群减少。
- SLE患者记忆CD8+ T细胞SLAMF7表达降低。
- SLAMF7交联可增强SLE患者CD8+ T细胞脱颗粒、IFNγ产生及细胞毒活性。
核心结论
- SLE患者CD8+ T细胞对病毒抗原的激活存在缺陷,通过特异性单克隆抗体激活SLAMF7可恢复其抗病毒效应功能至正常水平,为潜在治疗选择。
研究设计与样本
- 研究比较SLE患者与健康对照外周血分离的CD8+ T细胞亚群分布、SLAMF7表达及胞溶酶(穿孔素、颗粒酶A、颗粒酶B)表达,采用流式细胞术分析。
- 评估病毒抗原刺激下CD107a表达与IFNγ产生(加或不加抗SLAMF7抗体),并用流式细胞术检测SLAMF7交联后的抗病毒细胞毒活性。
主要发现
- SLE患者外周血CD8+ T细胞亚群分布改变,效应细胞亚群减少。
- SLE患者记忆CD8+ T细胞SLAMF7表达降低,该受体是效应CD8+ T细胞的特征表面标志。
- SLAMF7交联增加SLE患者及健康对照CD8+ T细胞脱颗粒能力和抗原刺激后IFNγ阳性细胞比例。
- SLAMF7交联促进病毒抗原刺激下对靶细胞的细胞毒性裂解。
临床怎么用
- SLAMF7激活可能作为恢复SLE患者抗病毒CD8+ T细胞效应功能的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Effector CD8+ T cell function is impaired in systemic lupus erythematosus (SLE) and is associated with a compromised ability to fight infections. Signaling lymphocytic activation molecule family member 7 (SLAMF7) engagement has been shown to enhance natural killer cell degranulation. This study was undertaken to characterize the expression and function of SLAMF7 on CD8+ T cell subsets isolated from the peripheral blood of SLE patients and healthy subjects. METHODS: CD8+ T cell subset distribution, SLAMF7 expression, and expression of cytolytic enzymes (perforin, granzyme A [GzmA], and GzmB) on cells isolated from SLE patients and healthy controls were analyzed by flow cytometry. CD107a expression and interferon-γ (IFNγ) production in response to viral antigenic stimulation in the presence or absence of an anti-SLAMF7 antibody were assessed by flow cytometry. Antiviral cytotoxic activity in response to SLAMF7 engagement was determined using a flow cytometry-based assay. RESULTS: The distribution of CD8+ T cell subsets was altered in the peripheral blood of SLE patients, with a decreased effector cell subpopulation. Memory CD8+ T cells from SLE patients displayed decreased amounts of SLAMF7, a surface receptor that characterizes effector CD8+ T cells. Ligation of SLAMF7 increased CD8+ T cell degranulation capacity and the percentage of IFNγ-producing cells in response to antigen challenge in SLE patients and healthy controls. Moreover, SLAMF7 engagement promoted cytotoxic lysis of target cells in response to stimulation with viral antigens. CONCLUSION: CD8+ T cell activation in response to viral antigens is defective in SLE patients. Activation of SLAMF7 through a specific monoclonal antibody restores CD8+ T cell antiviral effector function to normal levels and thus represents a potential therapeutic option in SLE.
引用
- Comte D, Karampetsou MP, Yoshida N, et al. Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017. PMID: 28076903. doi:10.1002/art.40038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。